Sema4 and CM Life Sciences Announce the Filing of the Schedule-14A Proxy Statement in Connection with the Proposed Merger

Author's Avatar
May 06, 2021

Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, and CM Life Sciences (Nasdaq: CMLF), a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today announced the filing of the preliminary proxy statement related to their proposed business combination.